Aerovate TherapeuticsAVTE
AVTE
About: Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Employees: 51
0
Funds holding %
of 6,790 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
356% more call options, than puts
Call options by funds: $301K | Put options by funds: $66K
28% more capital invested
Capital invested by funds: $45.2M [Q2] → $57.8M (+$12.6M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
1.26% more ownership
Funds ownership: 94.5% [Q2] → 95.76% (+1.26%) [Q3]
7% less funds holding
Funds holding: 81 [Q2] → 75 (-6) [Q3]
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Research analyst outlook
We haven’t received any recent analyst ratings for AVTE.
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences. Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity.
Neutral
Business Wire
1 month ago
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Aerovate Therapeutics, Inc. (NasdaqGM: AVTE) and Jade Biosciences. Pursuant to the terms of the agreement, shareholders of Aerovate will own approximately 1.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences.
Neutral
PRNewsWire
1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerovate Therapeutics, Inc. (NASDAQ: AVTE)'s merger with Jade Biosciences. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company.
Neutral
Business Wire
1 month ago
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
Neutral
Business Wire
1 month ago
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Aerovate (Nasdaq: AVTE) for possible breaches of fiduciary duty and other violations of law in its transaction with Jade. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Under the agreement, Aerovate stockholders are expected to own approximately 1.6% of the combined company, while Jade stockholders — including those investors participating in the pre-clo.
Neutral
GlobeNewsWire
4 months ago
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
Neutral
InvestorPlace
5 months ago
The 3 Hottest Stock Downgrades From Last Week
Wall Street's leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate its gains above 5500.
Neutral
GlobeNewsWire
5 months ago
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that “the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension (“PVR”) compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance.” Following this news, the price of the Company's stock dropped.
Neutral
GlobeNewsWire
5 months ago
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Charts implemented using Lightweight Charts™